{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:34:39Z","timestamp":1791380079319,"version":"4.3.3"},"reference-count":49,"publisher":"MedWorks Media","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Background\nPatients with Borderline Personality Disorder (BPD) have a high prevalence of mood disorders. Lamotrigine (LAM) is often used as an off-label therapeutic option for BPD. We aimed to conduct a systematic review and meta-analysis to assess the efficacy and tolerability of LAM for the treatment of BPD.\nMethods\nWe comprehensively searched electronic databases for eligible studies from the inception of databases to September 2019. Outcomes investigated were BPD dimensions, tolerability, and adverse events. Quality assessments were completed for the included studies. Data were summarized using random-effects model.\nResults\nOf the 619 records, five studies, including three randomized controlled trials (RCT; N = 330) were included for the qualitative analysis. A meta-analysis conducted on two RCTs measuring LAM efficacy at 12 weeks, showed no statistically significant difference at 12 weeks (SMD: \u22120.04; 95% CI: \u22120.49, 0.41; p = 0.87; I 2 = 38%) and at study endpoints (SMD: 0.18, 95%CI: \u22120.89, 1.26; p = 0.74; I 2 = 86%) as compared to placebo. Sensitivity analysis on three RCTs measuring impulsivity\/aggression showed no statistically significant difference between LAM and placebo (SMD: \u22121.84, 95% CI: \u22123.94, 0.23; p = 0.08; I 2 = 95%). LAM was well tolerated, and quality assessment of the included trials was good.\nConclusions\nOur results suggest there is limited data regarding efficacy of lamotrigine in BPD. There was no consistent evidence of lamotrigine\u2019s efficacy for the core symptom domains of BPD. Future studies should focus on examining targeted domains of BPD to clarify sub-phenotypes and individualized treatment for patients with BPD.<\/jats:p>","DOI":"10.64719\/pb.4375","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"118-136","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Tolerability of Lamotrigine in Borderline Personality Disorder: A Systematic Review and Meta-Analysis"],"prefix":"10.64719","volume":"50","author":[{"given":"Mehak","family":"Pahwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas A","family":"Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boney","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Seshadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle J","family":"Gerberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"Frye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balwinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","unstructured":"Diagnostic and statistical manual of mental disorders (DSM-5\u00ae) 2013 APA. American Psychiatric Pub."},{"key":"ref2","unstructured":"Torgersen S. American Psychiatric Publishing Textbook of Personality Disorders. Washington, DC: American Psychiatric Publishing; 2014."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Johnson JG, Cohen P, Kasen S, Skodol AE, Oldham JM. Cumulative prevalence of personality disorders between adolescence and adulthood. Acta Psychiatr Scand. 2008;118(5):410\u2013413.","DOI":"10.1111\/j.1600-0447.2008.01231.x"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Gunderson JG, Herpertz SC, Skodol AE, Torgersen S, Zanarini MC. Borderline personality disorder. Nat Rev Dis Primers. 2018;4:18029.","DOI":"10.1038\/nrdp.2018.29"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Grant BF, Chou SP, Goldstein RB et al. Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2008;69(4):533\u2013545.","DOI":"10.4088\/JCP.v69n0404"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Zimmerman M, Chelminski I, Dalrymple K, Rosenstein L. Principal diagnoses in psychiatric outpatients with borderline personality disorder: Implications for screening recommendations. Ann Clin Psychiatry. 2017;29(1):54\u201360.","DOI":"10.1177\/104012371702900110"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Chanen AM, Jovev M, Djaja D et al. Screening for borderline personality disorder in outpatient youth. J Pers Disord. 2008;22(4):353\u2013364.","DOI":"10.1521\/pedi.2008.22.4.353"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Zimmerman M, Chelminski I, Young D. The frequency of personality disorders in psychiatric patients. Psychiatr Clin North Am. 2008;31(3):405\u2013420, vi.","DOI":"10.1016\/j.psc.2008.03.015"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Korzekwa MI, Dell PF, Links PS, Thabane L, Webb SP. Estimating the prevalence of borderline personality disorder in psychiatric outpatients using a two-phase procedure. Compr Psychiatry. 2008;49(4):380\u2013386.","DOI":"10.1016\/j.comppsych.2008.01.007"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Fossati A, Maffei C, Bagnato M et al. Patterns of covariation of DSM-IV personality disorders in a mixed psychiatric sample. Compr Psychiatry. 2000;41(3):206\u2013215.","DOI":"10.1016\/S0010-440X(00)90049-X"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Marinangeli MG, Butti G, Scinto A et al. Patterns of comorbidity among DSM-III-R personality disorders. Psychopathology. 2000;33(2):69\u201374.","DOI":"10.1159\/000029123"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Grilo CM, McGlashan TH, Quinlan DM, Walker ML, Greenfeld D, Edell WS. Frequency of personality disorders in two age cohorts of psychiatric inpatients. Am J Psychiatry. 1998;155(1):140\u2013142.","DOI":"10.1176\/ajp.155.1.140"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Paruk L, Janse van Rensburg ABR. Inpatient management of borderline personality disorder at Helen Joseph Hospital, Johannesburg. S Afr J Psychiatr. 2016;22(1):678.","DOI":"10.4102\/sajpsychiatry.v22i1.678"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Gross R, Olfson M, Gameroff M et al. Borderline personality disorder in primary care. Arch Intern Med. 2002;162(1):53\u201360.","DOI":"10.1001\/archinte.162.1.53"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Chaput YJ, Lebel MJ. Demographic and clinical profiles of patients who make multiple visits to psychiatric emergency services. Psychiatr Serv. 2007;58(3):335\u2013341.","DOI":"10.1176\/ps.2007.58.3.335"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Tomko RL, Trull TJ, Wood PK, Sher KJ. Characteristics of borderline personality disorder in a community sample: comorbidity, treatment utilization, and general functioning. J Pers Disord. 2014;28(5):734\u2013750.","DOI":"10.1521\/pedi_2012_26_093"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Amad A, Ramoz N, Thomas P, Jardri R, Gorwood P. Genetics of borderline personality disorder: systematic review and proposal of an integrative model. Neurosci Biobehav Rev. 2014;40:6\u201319.","DOI":"10.1016\/j.neubiorev.2014.01.003"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Reichborn-Kjennerud T, Czajkowski N, Roysamb E et al. Major depression and dimensional representations of DSM-IV personality disorders: a population-based twin study. Psychol Med. 2010;40(9):1475\u20131484.","DOI":"10.1017\/S0033291709991954"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Torgersen S, Lygren S, Oien PA et al. A twin study of personality disorders. Compr Psychiatry. 2000;41(6):416\u2013425.","DOI":"10.1053\/comp.2000.16560"},{"key":"ref20","unstructured":"Practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Association. Am J Psychiatry. 2001;158(10 Suppl):1\u201352. American Psychiatric Association Practice G."},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Akiskal HS. Demystifying borderline personality: critique of the concept and unorthodox reflections on its natural kinship with the bipolar spectrum. Acta Psychiatr Scand. 2004;110(6):401\u2013407.","DOI":"10.1111\/j.1600-0447.2004.00461.x"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Gunderson JG, Weinberg I, Daversa MT et al. Descriptive and longitudinal observations on the relationship of borderline personality disorder and bipolar disorder. Am J Psychiatry. 2006;163(7):1173\u20131178.","DOI":"10.1176\/ajp.2006.163.7.1173"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Bloom R, Amber KT. Identifying the incidence of rash, Stevens-Johnson syndrome and toxic epidermal necrolysis in patients taking lamotrigine: a systematic review of 122 randomized controlled trials. An Bras Dermatol. 2017;92(1):139\u2013141.","DOI":"10.1590\/abd1806-4841.20175070"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Bowden CL, Singh V. Lamotrigine (Lamictal IR) for the treatment of bipolar disorder. Expert Opin Pharmacother. 2012;13(17):2565\u20132571.","DOI":"10.1517\/14656566.2012.741590"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Tritt K, Nickel C, Lahmann C et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. Journal of Psychopharmacology. 2005;19(3):287\u2013291.","DOI":"10.1177\/0269881105051540"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Reich DB, Zanarini MC, Bieri KA. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. International Clinical Psychopharmacology. 2009;24(5):270\u2013275.","DOI":"10.1097\/YIC.0b013e32832d6c2f"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Crawford MJ, Sanatinia R, Barrett B et al. Lamotrigine for people with borderline personality disorder: a RCT. Health Technology Assessment (Winchester, England) 2018;22(17):1\u201368.","DOI":"10.3310\/hta22170"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264\u2013269. W264.","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"ref29","unstructured":"Higgins J. Cochrane handbook for systematic reviews of interventions. 2011 Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook.org."},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. Journal of clinical epidemiology. 2000;53(11):1119\u20131129.","DOI":"10.1016\/S0895-4356(00)00242-0"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials. 1986;7(3):177\u2013188.","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ: British Medical Journal. 2003;327(7414):557.","DOI":"10.1136\/bmj.327.7414.557"},{"key":"ref33","unstructured":"Schwarzer G. meta: An R package for meta-analysis. R News. 2007;7(3):40\u201345."},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. Journal of Statistical Software. 2010;36(3):1\u201348.","DOI":"10.18637\/jss.v036.i03"},{"key":"ref35","unstructured":"R: A language and environment for statistical computing. R Core Team, R Foundation for Statistical Computing; Vienna, Austria: 2019. [computer program]. https:\/\/www.R-project.org\/"},{"key":"ref36","unstructured":"RStudio: Integrated Development Environment for R. RStudio Team, RStudio Inc.; Boston, MA: 2016. [computer program]. http:\/\/www.rstudio.com\/"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Weinstein W, Jamison KL. Retrospective case review of lamotrigine use for affective instability of borderline personality disorder. CNS Spectrums. 2007;12(3):207\u2013210.","DOI":"10.1017\/S1092852900020927"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Preston GA, Marchant BK, Reimherr FW, Strong RE, Hedges DW. Borderline personality disorder in patients with bipolar disorder and response to lamotrigine. Journal of Affective Disorders. 2004;79(1\u20133):297\u2013303.","DOI":"10.1016\/S0165-0327(02)00358-0"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Leiberich P, Nickel MK, Tritt K, Gil FP. Lamotrigine treatment of aggression in female borderline patients, Part II: An 18-month follow-up. Journal of Psychopharmacology. 2008;22(7):805\u2013808.","DOI":"10.1177\/0269881107084004"},{"key":"ref40","unstructured":"Borderline personality disorder: Treatment and management. NICE Clinical Guideline. 2009:78. NICE."},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Lieb K, Vollm B, Rucker G, Timmer A, Stoffers JM. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry. 2010;196(1):4\u201312.","DOI":"10.1192\/bjp.bp.108.062984"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Stone MH. Borderline Personality Disorder: Clinical Guidelines for Treatment. Psychodyn Psychiatry. 2019;47(1):5\u201326.","DOI":"10.1521\/pdps.2019.47.1.5"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. Journal of Affective Disorders. 1998;51(3):333\u2013343.","DOI":"10.1016\/S0165-0327(99)00007-5"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Moeller KE, Din A, Wolfe M, Holmes G. Psychotropic medication use in hospitalized patients with borderline personality disorder. Mental Health Clinician. 2016;6(2):68\u201374.","DOI":"10.9740\/mhc.2016.03.68"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Stone MH. Borderline Personality Disorder: Therapeutic Factors. Psychodyn Psychiatry. 2016;44(4):505\u2013539.","DOI":"10.1521\/pdps.2016.44.4.505"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Vita A, De Peri L, Sacchetti E. Antipsychotics, antidepressants, anticonvulsants, and placebo on the symptom dimensions of borderline personality disorder: A meta-analysis of randomized controlled and open-label trials. Journal of Clinical Psychopharmacology. 2011;31(5):613\u2013624.","DOI":"10.1097\/JCP.0b013e31822c1636"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Gunderson JG, Choi-Kain LW. Medication Management for Patients With Borderline Personality Disorder. Am J Psychiatry. 2018;175(8):709\u2013711.","DOI":"10.1176\/appi.ajp.2018.18050576"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Ng F, Hallam K, Lucas N, Berk M. The role of lamotrigine in the management of bipolar disorder. Neuropsychiatr Dis Treat. 2007;3(4):463\u2013474.","DOI":"10.2147\/NDT.A920"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Zanarini MC, Frankenburg FR, Hennen J, Reich DB, Silk KR. Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission. Am J Psychiatry. 2004;161(11):2108\u20132114.","DOI":"10.1176\/appi.ajp.161.11.2108"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:27:05Z","timestamp":1791314825000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/efficacy-and-tolerability-of-lamotrigine-in-borderline-personality-disorder-a-systematic-review-and-meta-analysis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":49,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4375","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}